ストックスクリーナーアプリを入手
1.14
4.59%
0.05
アフターアワーズ：
1.18
0.04
+3.51%
前日終値:
$1.09
開ける：
$1.1
24時間の取引高:
1.21M
Relative Volume:
0.99
時価総額：
$123.34M
収益：
$4.35M
当期純損益:
$-45.53M
株価収益率:
-1.0556
EPS:
-1.08
ネットキャッシュフロー:
$-44.79M
1週間 パフォーマンス:
-3.39%
1か月 パフォーマンス:
-7.32%
6か月 パフォーマンス:
+35.26%
1年 パフォーマンス:
+29.56%
1日の値動き範囲:
$1.09
$1.175
1週間の範囲:
$1.07
$1.225
52週間の値動き範囲:
$0.7201
$1.80
Lucid Diagnostics Inc Stock (LUCD) Company Profile
LUCD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.14 | 127.67M | 4.35M | -45.53M | -44.79M | -1.08 |
|
ABT
Abbott Laboratories
|
120.51 | 232.44B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.65 | 153.66B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
388.90 | 150.87B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.53 | 114.55B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.18 | 46.22B | 5.54B | 4.18B | 623.10M | 7.00 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-12-27 | 開始されました | Ascendiant Capital Markets | Buy |
| 2021-11-08 | 開始されました | BTIG Research | Buy |
| 2021-11-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 開始されました | Needham | Buy |
Lucid Diagnostics Inc (LUCD) 最新ニュース
Lucid says meeting scheduled to determine Medicare coverage for cancer test - MSN
LUCD’s 2025 Market Dance: Up 26.00% – Time to Invest? - investchronicle.com
what makes lucid diagnostics inc. stock price move sharply3x Growth Potential - Newser
Esophageal Cancer Detection Revolution: Lucid's Medicare Milestone and Its Market Impact - AInvest
Lucid says AdCom meeting set to determine cancer test coverage - Seeking Alpha
Lucid Diagnostics Inc. shares fall 5.98% intraday as MolDX convenes expert medical panel on Medicare. - AInvest
MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test - PR Newswire
How Lucid Diagnostics Inc. stock performs during market volatilityRisk Managed Trading Strategy - Newser
What makes Lucid Diagnostics Inc. stock price move sharplyInvestor Favorite Picks - Newser
Why Lucid Diagnostics Inc. stock attracts strong analyst attentionRisk Aware High Growth Picks - Newser
Brokerages Set Lucid Diagnostics Inc. (NASDAQ:LUCD) Price Target at $3.55 - Defense World
[New] Lucid Stock Price Prediction 2024, 2025 To 2050 - Exla Resources
Lucid Diagnostics Inc.(NasdaqCM: LUCD) added to Russell Small Cap Comp Growth Index - MarketScreener
Lucid Diagnostics Inc.(NasdaqCM: LUCD) added to Russell 3000 Index - MarketScreener
Is Lucid Diagnostics, Inc. technically bullish or bearish? - MarketsMojo
Lucid Diagnostics Holds Annual Stockholders Meeting - TipRanks
Leading California Hospital Network Launches Revolutionary 3-Minute Cancer Detection Test from Lucid Diagnostics - Stock Titan
Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test - Finansavisen
119,887 Shares in Lucid Diagnostics Inc. (NASDAQ:LUCD) Acquired by Citadel Advisors LLC - Defense World
Ascendiant Capital Markets Issues Positive Forecast for Lucid Diagnostics (NASDAQ:LUCD) Stock Price - Defense World
Ascendiant Capital raises Lucid Diagnostics stock price target to $7.75 By Investing.com - Investing.com South Africa
Ascendiant Capital raises Lucid Diagnostics stock price target to $7.75 - Investing.com Australia
Lucid Diagnostics (LUCD) Stock Maintained at Buy by Ascendiant Capital | LUCD Stock News - GuruFocus
Lucid Diagnostics (LUCD) Target Price Increased by Ascendiant | - GuruFocus
Lucid Diagnostics Files For Offering Of 36 Million Shares Of Common Stock - MarketScreener
Pavmed's Veris Health Signs Long-Term Partnership Deal With Ohio State University Hospital - marketscreener.com
Lucid Diagnostics Enters $25M Sales Agreement - TipRanks
Lucid Diagnostics joins Russell 2000 and 3000 indexes - Mugglehead Magazine
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes - The Malaysian Reserve
Lucid Diagnostics to Join Russell 2000, Russell 3000 Indexes - marketscreener.com
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes By Investing.com - Investing.com South Africa
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes - Investing.com Australia
Lucid Diagnostics (LUCD) Joins Russell 2000 and Russell 3000 Indexes | LUCD Stock News - GuruFocus
Lucid Diagnostics (LUCD) Joins Russell 2000 and Russell 3000 Ind - GuruFocus
Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.50 Consensus Price Target from Brokerages - Defense World
Certain Options of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2025. - marketscreener.com
Certain Common Stock of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2025. - marketscreener.com
Insider Buying: Dennis Matheis Acquires 350,000 Shares of Lucid Diagnostics Inc (LUCD) - GuruFocus
Certain Series B-1 Convertible Preferred Stock of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2025. - MarketScreener
Lucid Diagnostics (LUCD) Director Acquires Significant Shares | - GuruFocus
Lucid Diagnostics (LUCD) Director Acquires Significant Shares | LUCD Stock News - GuruFocus
Unraveling Lucid Diagnostics' Mysterious 15% Surge: No Fundamental News, But Clues in the Chaos - AInvest
Lucid Diagnostics Files Shelf Registration for Secondary Sale of 37 Million Shares by Convertible Note Holders - marketscreener.com
Lucid Diagnostics (LUCD) Files to Sell 36.98 Million Shares | LU - GuruFocus
Lucid Diagnostics Files Prospectus For Potential Offer, Sale From Time To Time Of Up To 37 Million Shares Of Common Stock By Selling Stockholders - marketscreener.com
Lucid Diagnostics (LUCD) Files to Sell 36.98 Million Shares | LUCD Stock News - GuruFocus
Lucid Diagnostics’ SWOT analysis: stock faces reimbursement hurdles amid market potential - Investing.com Nigeria
Cantor Fitzgerald maintains Lucid Diagnostics stock Overweight - Investing.com Australia
Cantor Fitzgerald maintains Lucid Diagnostics stock Overweight By Investing.com - Investing.com India
Lucid Diagnostics Inc (LUCD) 財務データ
収益
当期純利益
現金流量
EPS
1.67%
0.94%
大文字化:
|
ボリューム (24 時間):